stage 3. 3 However, in the case reported here, the tractional component progressed even without the appearance of vascular activity. This finding is not unique when using intravitreal bevacizumab in vascular retinopathies. Fibrosis, 7 days after intravitreal bevacizumab, had been reported in eyes with proliferative diabetic retinopathy, 4 as well as acute contraction of the fibrovascular membrane in ROP. 5 Kong et al reported in a pathologic study that intravitreal bevacizumab in zone I, stage 2 plus ROP did not show inflammation, necrosis, or degeneration. 6 Contraction of large fibrovascular membranes (stage 3, more than 6 h extension) may well lead to a tractional retinal detachment as shown in this case and in two cases in a series by Kusaka et al.
1,5
Antiangiogenic therapy had been proposed as a valuable resource in the treatment of advanced cases of acute phase ROP; however, we must remember that such use is off-label, and long-term ocular and systemic side effects in this population are unknown. 2, 6, 7 The value of the current report is pointing out that the development of a tractional retinal detachment is a potential complication of such therapy. Postsurgical evolution of these cases differs from the cases treated only with photocoagulation. Choroidal neovascularization (CNV) secondary to colobomas are rare and have been treated with laser photocoagulation, photodynamic therapy (PDT), or merely observed. [1] [2] [3] [4] To the best of our knowledge, this is the first report of treatment of CNV secondary to a coloboma with intravitreal anti-vascular endothelial growth factor therapy.
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Case report
A 36-year-old man presented with reduced vision in the right eye of 1-month duration. The left eye had microphthalmos. His best-corrected visual acuity (BCVA) was 6/36 OD. Clinical evaluation of the right eye revealed an inferior retinochoroidal coloboma, extending up to the inferior disc margin and macula. Active subfoveal CNV with submacular haemorrhage was noted (Figure 1a) , which was further evidenced by fluorescein angiography (FA) (Figure 1b ) and optical coherence tomography (OCT) (Figure 1c) . The patient opted for and was administered 1.25 mg of intravitreal bevacizumab (Avastin, Genentech, San Francisco, CA, USA).
One month later, the patient presented with an improved BCVA of 6/24 OD. Fundus examination, FA, and OCT revealed partially regressed CNV, and the patient was re-treated by injecting intravitreal bevacizumab in the right eye. At the final review, a year later, his BCVA was 6/9 OD and the CNV was noted to have completely regressed clinically, angiographically, and tomographically (Figures 1d-f) .
Comment CNV, a rare complication, usually develops at the junction between the normal retina and the coloboma, as also observed in our case. 1 Bruch's membrane disruption and retinal pigment epithelium displacement at the margin of the coloboma allow migration of choroidal neovascular tissue into the subretinal space at this site. 1 The paucity of reports coupled with the age at presentation varying from the first to the seventh decade has led to the specific trigger for neovascularization remaining unestablished.
Of the five eyes treated with laser photocoagulation, two showed improvement in vision, with the rest remaining at the same level.
1 PDT improved the vision in a child. 4 Only one of the four conservatively managed cases reported stabilization of vision.
1,3 Bevacizumab has been used off-label, as intravitreal therapy for CNV, successfully. 5 We report on the regression of CNV associated with a retinochoroidal coloboma in a uni-ocular patient, who received two injections of intravitreal bevacizumab and showed significant visual improvement over a year.
